Overview
ARQT market data
Price History
ARQT price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$0.13 Diluted earnings per share over the trailing twelve months.
- Beta
- 1.50 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- — Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $13.70 – $31.77 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · source Twelve Data /statistics · market cap $3.4K · P/B 18.77 · P/S 8.16.
Company news
8-K filing — Arcutis Biotherapeutics, Inc. (ARQT)SEC EDGAR · Jul 16, 2026, 8:25 PM
Arcutis Expands Board of Directors with Appointment of Chris PeetzGlobenewswire Inc · Jul 16, 2026, 1:15 PM
FDA Accepts Supplemental New Drug Application For Arcutis Biotherapeutics' ZORYVE Cream 0.05%Benzinga · Jul 8, 2026, 12:05 PM
Antag Therapeutics Elects Keith Leonard as Chairman of its Board of DirectorsGlobenewswire Inc · Jun 9, 2026, 11:15 AM
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Globenewswire Inc · Jun 5, 2026, 8:15 PM
Arcutis Management to Present at Goldman Sachs 47th Annual Global Healthcare ConferenceGlobenewswire Inc · May 26, 2026, 8:15 PM
Arcutis Announces First Quarter 2026 Financial Results and Provides Business UpdateGlobenewswire Inc · May 6, 2026, 8:05 PM